Neuropsychiatric and cognitive effects of the COVID-19 outbreak on multiple sclerosis patients

Akhoundi, Fahimeh Haji; Sahraian, Mohammad Ali; Moghadasi, Abdorreza Naser

doi:10.1016/j.msard.2020.102164

Cited by 48 publications

(61 citation statements)

References 9 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As occurring in general population, fever and dyspnea were more common in MS patients hospitalized for COVID-19 while anosmia/ageusia and headache were more common in patients who were not hospitalized [64]. Considering that cognitive dysfunction usually affects up to 70% of MS patients, it is not surprising that these patients are vulnerable to develop neuropsychiatric symptoms during COVID-19 pandemic [66]. Thus, MS specialists should adapt a strategy to monitor MS patients for neuropsychiatric complications and also opt for applicable treatment options [66].…”

Section: Modification Of the Neurological Disease And Care Strategiesmentioning

confidence: 92%

“…Considering that cognitive dysfunction usually affects up to 70% of MS patients, it is not surprising that these patients are vulnerable to develop neuropsychiatric symptoms during COVID-19 pandemic [66]. Thus, MS specialists should adapt a strategy to monitor MS patients for neuropsychiatric complications and also opt for applicable treatment options [66]. Acute and long term effects of COVID-19 on disease course of MS population should a subject for future research.…”

Section: Modification Of the Neurological Disease And Care Strategiesmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable?

2020

View full text Add to dashboard Cite

Neurological disorders and coronavirus 2019 (COVID-19) pandemic are two conditions with a recent well-documented association. Intriguing evidences showed that COVID-19 infection can modify clinical spectrum of manifested neurological disorders but also it plays a crucial role in the development of future diseases as long-tem consequences. In this viewpoint review, we aimed to assess the vulnerability to SARS-CoV-2 infection and development of COVID-19 among neurological disorders. With this in mind, we tested the hypothesis that age rather than neuropathology itself could be decisive in neurodegenerative diseases such as Parkinson's disease, whereas neuropathology rather than age may be critical in neuroimmunological diseases such as Multiple Sclerosis. Highlighting the role of potential susceptibility or protection factors from this disastrous infection, we also stratify the risk for future neurodegeneration.

show abstract

Section: Modification Of the Neurological Disease And Care Strategiesmentioning

confidence: 92%

Section: Modification Of the Neurological Disease And Care Strategiesmentioning

confidence: 99%

COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable?

2020

View full text Add to dashboard Cite

show abstract

“…Individuals with Multiple Sclerosis (MS) are typically on immunosuppressive/modulating medication placing them at-risk of infection from viruses [ 4 ] and are hypothetically at-risk for developing more severe forms of COVID-19 [ 5 ]. These individuals additionally have increased vulnerability to the neuropsychiatric concomitants of COVID-19, due to pre-existing neuropsychiatric symptomotology [ 6 ]. The COVID-19 pandemic has shown enormous psychological and social impact in the general population [ 7 ], not unlike other infectious diseases [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

The emotional impact of the COVID-19 pandemic on individuals with progressive multiple sclerosis

et al. 2020

View full text Add to dashboard Cite

Objective Individuals with pre-existing chronic illness have shown increased anxiety and depression due to COVID-19. Here, we examine the impact of the COVID-19 pandemic on emotional symptomatology and quality of life in individuals with Progressive Multiple Sclerosis (PMS). Methods Data were obtained during a randomized clinical trial on rehabilitation taking place at 11 centers in North America and Europe. Participants included 131 individuals with PMS. Study procedures were interrupted in accordance with governmental restrictions as COVID-19 spread. During study closure, a COVID Impact Survey was administered via telephone or email to all participants, along with measures of depressive symptoms, anxiety symptoms, quality of life, and MS symptomatology that were previously administered pre-pandemic. Results 4% of respondents reported COVID-19 infection. No significant changes were noted in anxiety, quality of life, or the impact of MS symptomatology on daily life from baseline to lockdown. While total HADS-depression scores increased significantly at follow-up, this did not translate into more participants scoring above the HADS threshold for clinically significant depression. No significant relationships were noted between disease duration, processing speed ability or EDSS, and changes in symptoms of depression or anxiety. Most participants reported the impact of the virus on their psychological well-being, with a little impact on financial well-being. The perceived impact of the pandemic on physical and psychological well-being was correlated with the impact of MS symptomatology on daily life, as well as changes in depression. Conclusions Overall, little change was noted in symptoms of depression or anxiety or overall quality of life.

show abstract

“…Moreover, a previous study indicated that the hospital staff who were quarantined due to the possibility of a contact with suspected severe acute respiratory syndrome (SARS) cases had an increased prevalence of acute stress disorder 3 . On the other hand, patients with chronic diseases such as MS are known to be affected more severely by natural disasters and crises 7 . In such patients, the psychological and cognitive deterioration associated with numerous factors including keeping abreast of morbidity and mortality rates on a daily basis, social isolation and sense of loneliness, minimal access to all services including healthcare services and clinical visits, termination of public transport modes, and the challenges in access to drugs and in drug management have reached an alarming level.…”

Section: Introductionmentioning

confidence: 99%

“…To our knowledge, there are very few studies reporting on the impact of the COVID-19 pandemic on fatigue, sleep quality, depression, anxiety, quality of life, and cognitive functions in MS patients 7,8 . The aim of this study was to investigate the neuropsychiatric effects of the COVID-19 pandemic in MS patients and to analyze the risk factors contributing to psychological stress.…”

Section: Introductionmentioning

confidence: 99%

Neuropsychiatric changes during the COVID-19 pandemic in multiple sclerosis patients

Demir

Bilek

Balgetir

2020

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Background: This study reported on a variety of psychological reactions related to anxiety, sleep quality, depression, fatigue, and quality of life in individuals with multiple sclerosis (MS), related to the Covid-19 quarantine experience. Objective: The aim of this study was to investigate the neuropsychiatric effects of the COVID-19 pandemic in MS patients and to analyze the risk factors contributing to psychological stress. Methods: The study was designed as a prospective, cross-sectional survey study. Multiple assessment tools that are used in neurological practice, including Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Fatigue Impact Scale (FIS), Pittsburgh Sleep Quality Index (PSQI), and Multiple Sclerosis Quality of Life-54 (MSQOL-54) were administered prospectively both during the early and the peak stages of COVID-19 outbreak (ESO and PSO, respectively). The survey forms were designed using SurveyMonkey and the participants were participating in the survey via a web link and QR code. Results: Fifty patients were included in the study. BDI scores, PSQI and FSI measurements, cognitive and social subscale scores and total FIS score, MSQOL-54 measurements, physical and mental subscale scores, and total MSQOL-54 score at PSO were significantly different than those at ESO. The body mass index values of the patients increased significantly at PSO compared to those measured at ESO. Conclusions: The results provide a basis for the development of psychological interventions that could minimize the prevalence of sleep disorders and depression and could improve patients’ quality of life during the outbreak.

show abstract

Neuropsychiatric and cognitive effects of the COVID-19 outbreak on multiple sclerosis patients

Cited by 48 publications

References 9 publications

COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable?

COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable?

The emotional impact of the COVID-19 pandemic on individuals with progressive multiple sclerosis

Neuropsychiatric changes during the COVID-19 pandemic in multiple sclerosis patients

Contact Info

Product

Resources

About